Science

Science news

June 2011

Encouraging results seen in cancer trial exploring the role of CVT-E002TM  in reducing the incidence and severity of acute respiratory infection for Chronic Lymphocytic Leukemia patients.

  • CVT-E002 showed a statistically significant reduction in the incidence of moderate to severe acute respiratory infection (ARI) symptoms (relative risk reduction of 20.1%; p = 0.02)
  • CVT-E002 demonstrated an increased immunological response; greater seroconversion (antibody levels) was observed against nine common upper respiratory viral pathogens with CVT-E002 versus placebo (16% vs. 7%, p = 0.04)
  • CVT-E002 treated patients had a significantly reduced relative risk of Serious Adverse Events (SAEs) (Grade 3+ toxicities; p = 0.02) demonstrating an unexpected favourable safety-related finding

 

    January 2011

    DILEXAPONANTM poster wins second place at annual Scripps conference

    • Afexa scientists attended the 8th Annual Natural Supplements: An Evidence-Based Update at the Scripps Center for Integrative Medicine
    • DILEXAPONAN, (LIP-01), a proprietary formulation consisting of multiactive components extracted from Coptis chinensis and Ilex kudingcha, demonstrates lipid-lowering effects in pre-clinical and clinical studies” won 2nd place in its category.

     

    November 2010

    Afexa co-sponsors science forum, "Botanical Drug Discovery: Breakthroughs in Polymolecular Therapeutics" in Toronto, ON.

    • Afexa, together with MaRS Discovery District and with the support of PEI BioAlliance, McMaster University, the University of Alberta, Alberta Innovates, the Canadian Institutes for Health Research (CIHR), the Innovation Institute of Ontario, BIOTECanada, and AVAC, organized and hosted the one-day science event
    • The workshop was initiated to promote the exchange of knowledge, ideas and policy perspectives in the rapidly-evolving field of polymolecular drugs, and to foster the development of new, successful collaborations between sectors.
    • Both Canadian and International speakers attended and presented their original research and policy perspectives to an audience of professionals and key opinion leaders with diverse backgrounds and perspectives

     

    October 2010

    Afexa collaborators present data from Afexa's new lipid formulation at Canadian conference

    • A collaborator from the University of Alberta presented new data at the Canadian Cardiovascular Congress, held in Montreal

     

    May 2010

    Afexa presents research data at Canadian scientific meetings

    • Clinical results from our previous REMEMBER-FX studies were presented at the joint meeting of the Canadian College of Neuropsychopharmacology and the Canadian Association for Neuroscience in Ottawa ON
    • Seven research presentations (posters and oral presentations) were presented at the 10th Annual Conference of the Natural Health Products Research Society of Canada in Halifax NS

     

    February 2010

    Afexa initiates new clinical trial collaboration with a CRO specializing in clinical studies involving over-the-counter products, natural health products, functional foods and botanical drug.

    CRO will collaborate on our existing trial running at the University of Alberta which investigates the effect of DILEXAPONAN (previously referred to as LIP-01) on lipid and cholesterol levels

     

    January 2010

    Afexa scientific posters win prizes at Scripps Center for Integrative Medicine conference for their high quality of research and presentation

    • Afexa scientists attended the 7th Annual Natural Supplements: An Evidence-Based Update, a scientific conference hosted by the prestigious Scripps Center for Integrative Medicine
    • Clinical effects of North American ginseng extract (HT1001™) on memory function" won 2nd place in its category
    • Systematic review of randomized, double-blind, placebo-controlled clinical trials of daily dosing of a North American ginseng extract (CVT-E002)" won 3rd place in its category

    Afexa sponsors the 2010 Alberta Respiratory Disease Symposium

    • The 2010 Alberta Respiratory Disease Symposium (ARDS) will be held in Banff AB this April
    • Leading experts in the fields of asthma and allergy from across Alberta and Canada are slated to attend

     

    November 2009

    Afexa launches pilot clinical study to investigate DILEXAPONAN in lowering lipid and cholesterol levels

    • Afexa has initiated a clinical trial in the investigation of a new product, DILEXAPONAN, on lipid and cholesterol levels in healthy individuals at risk for metabolic syndrome
    • The study is being headed by a Professor of Endocrinology and Metabolism at the University of Alberta, and is designed to determine the optimal therapeutic dose of DILEXAPONAN for the reduction of lipid and cholesterol levels

    Preclinical research presented at oncology conference in New York

    • Preclinical data demonstrating that CVT-E002 (the active ingredient in COLD-FX) dose-dependently increases the lifespan of leukemic mice was presented at the 6th Annual Meeting of the Society of Integrative Oncology in New York
    • These data were part of a larger study published earlier this year in the Journal of the Society for Integrative Oncology

    Afexa publishes two research articles in special issue of the Open Nutraceuticals Journal

    • Data from two studies were recently published in a special issue of the Open Nutraceuticals Journal in honour of Dr. Tapan K. Basu
    • The Open Nutraceuticals Journal is an open-access online peer-reviewed journal that publishes preclinical and clinical studies on foods and supplements that provide medical health benefits and contribute to disease prevention
    • COLD-FX®Stimulates Cell Mediated Immune Response of Peripheral Leukocytes ex-vivo to Influenza Virus in National Hockey League Players" describes the beneficial effects of COLD-FX on immune stimulation in professional athletes
    • "Memory Enhancement from Two Weeks' Exposure to North American Ginseng Extract HT1001 in Young and Middle Aged Healthy Adults" describes the beneficial effects of REMEMBER-FX on memory function in younger and older healthy adults

     

    October 2009

    University of Alberta researcher presents early data from REMEMBER-FX®clinical trial

    • A University of Alberta collaborator and Principal Investigator of a clinical trial conducted on the cognitive and psychosocial effects of REMEMBER-FX in healthy adults presented some early data at the 5th Annual Canadian Conference on Dementia in Toronto ON this month

     

    August 2009

    McGill researchers demonstrate that CVT-E002 extends the longevity of tumor-bearing mice

    • Collaborators from McGill University have published a study demonstrating that administration of CVT-E002, the active ingredient of COLD-FX, stimulated non-specific immune parameters and increased the lifespan of leukemic mice
    • This is the first in vivo study to demonstrate the anti-leukemic properties of CVT-E002
    • Results were published in the Journal of the Society for Integrative Oncology

     

    May 2009

    Hometown researchers present preclinical data at San Diego conference

    • Collaborators from the University of Alberta presented preclinical data on the active ingredient of COLD-FX, CVT-E002, and immune stimulation in cultured cells this month at the American Thoracic Society (ATS) International Conference in San Diego, CA
    • The ATS International Conference is the world's premier educational program for clinicians and researchers in adult and pediatric pulmonary, critical care and sleep medicine

     

    March 2009

    University of Alberta researchers present COLD-FX data at Washington DC meeting on asthma, allergy and immune function

    • U of A collaborators recently attended the Annual Meeting of the American Academy of Allergy Asthma & Immunology in Washington DC, and presented recent data on the efficacy of CVT-E002 (the active ingredient of COLD-FX) on allergic immune response in a mouse model of asthma
    • COLD-FX for allergies is a new and exciting direction for Afexa, and is currently being explored in a Canada-wide multi-centre clinical trial

     

    February 2009

    Afexa and colleagues attend Canadian Natural Health Products Research Society conference in Vancouver

    • Afexa scientists and collaborators attended the 6th Natural Health Products Research Society conference in Vancouver, BC this month
    • Preclinical data on the immune-stimulating properties of CVT-E002 (COLD-FX) from two ongoing research projects were presented